SavedAdd your journal

Journals / Turkish Journal of Anaesthesiology and Reanimation / 2022 / Cilt: 50 - Sayı: 3

Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation

Bahar Sakızcı UYAR
Kerem ENSARİOĞLU
Emine Bahar KURT
Derya ÖZKAN
Serra ÖZBAL GÜNEŞ
Pages
228–231
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes.
📊
Key Findings & Data:In some cases, pulmonary fibrosis is observed after or during the disease.
💡
Conclusion & Impact:Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.

🔖

Cite This Article

UYAR, B. S., ENSARİOĞLU, K., KURT, E. B., ÖZKAN, D., GÜNEŞ, S. Ö. (2022). Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation. Turkish Journal of Anaesthesiology and Reanimation, Cilt: 50 - Sayı: 3, 228–231. https://ajindex.com/articles/418321

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. World Health Organization. HO (2020) coronavirus disease 2019 (COVID-19) situation report. Available at: https://co vid19.who.int/ 2. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020
  2. 8(5):475-481. [CrossRef] 3. Zhang C, Wu Z, Li JW, et al. Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19. J Med Virol. 2021
  3. 93(3):1378-1386. [CrossRef] 4. Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: anti-inflammatory and antifibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020
  4. 76(11):1615-1618. [CrossRef] 5. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018
  5. 379(8):797-798. [CrossRef] 6. Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020
  6. m3379. [CrossRef] 7. Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020
  7. 19(7):102568. [CrossRef] 8. Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int. 2016
  8. 36(6):881-889. [CrossRef] 9. Gatti M, Fusaroli M, Caraceni P, Poluzzi E, De Ponti F, Raschi E. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. Br J Clin Pharmacol. 2021
  9. 87(3):1533-1540. [CrossRef] 10. Tamura K, Nishioka S, Tamura N, Saito Z, Kuwano K. Successful treatment with methyl-prednisolone pulses for the late phase of COVID-19 with respiratory failure: A singlecenter case series. Respir Med Case Rep. 2020
  10. 101318. [CrossRef] 11. Li Y, Li H, Liu S, et al. Pirfenidone ameliorates lipopolysacchar ide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Mol Immunol. 2018
  11. [CrossRef] 12. Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome form